Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology

John Kurhanewicz; Daniel B Vigneron; Jan Henrik Ardenkjaer-Larsen; James A Bankson; Kevin Brindle; Charles H Cunningham; Ferdia A Gallagher; Kayvan R Keshari; Andreas Kjaer; Christoffer Laustsen; David A Mankoff; Matthew E Merritt; Sarah J Nelson; John M Pauly; Philips Lee; Sabrina Ronen; Damian J Tyler; Sunder S Rajan; Daniel M Spielman; Lawrence Wald; Xiaoliang Zhang; Craig R Malloy; Rahim Rizi

doi:10.1016/j.neo.2018.09.006

Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology

John Kurhanewicz, Daniel B Vigneron, Jan Henrik Ardenkjaer-Larsen, James A Bankson, Kevin Brindle, Charles H Cunningham, Ferdia A Gallagher, Kayvan R Keshari, Andreas Kjaer, Christoffer Laustsen, David A Mankoff, Matthew E Merritt, Sarah J Nelson, John M Pauly, Philips Lee, Sabrina Ronen, Damian J Tyler, Sunder S Rajan, Daniel M Spielman, Lawrence WaldXiaoliang Zhang, Craig R Malloy, Rahim Rizi

Cluster for Molecular Imaging

127 Citations (Scopus)

Abstract

This white paper discusses prospects for advancing hyperpolarization technology to better understand cancer metabolism, identify current obstacles to HP (hyperpolarized) 13C magnetic resonance imaging's (MRI's) widespread clinical use, and provide recommendations for overcoming them. Since the publication of the first NIH white paper on hyperpolarized 13C MRI in 2011, preclinical studies involving [1-13C]pyruvate as well a number of other 13C labeled metabolic substrates have demonstrated this technology's capacity to provide unique metabolic information. A dose-ranging study of HP [1-13C]pyruvate in patients with prostate cancer established safety and feasibility of this technique. Additional studies are ongoing in prostate, brain, breast, liver, cervical, and ovarian cancer. Technology for generating and delivering hyperpolarized agents has evolved, and new MR data acquisition sequences and improved MRI hardware have been developed. It will be important to continue investigation and development of existing and new probes in animal models. Improved polarization technology, efficient radiofrequency coils, and reliable pulse sequences are all important objectives to enable exploration of the technology in healthy control subjects and patient populations. It will be critical to determine how HP 13C MRI might fill existing needs in current clinical research and practice, and complement existing metabolic imaging modalities. Financial sponsorship and integration of academia, industry, and government efforts will be important factors in translating the technology for clinical research in oncology. This white paper is intended to provide recommendations with this goal in mind.

Original language	English
Journal	Neoplasia (New York, N.Y.)
Volume	21
Issue number	1
Pages (from-to)	1-16
Number of pages	16
ISSN	1522-8002
DOIs	https://doi.org/10.1016/j.neo.2018.09.006
Publication status	Published - Jan 2019

Keywords

Animals
Carbon Isotopes
Disease Models, Animal
Humans
Magnetic Resonance Imaging/methods
Neoplasms/diagnosis
Reproducibility of Results
Translational Medical Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.neo.2018.09.006Licence: CC BY-NC-ND

http://europepmc.org/articles/pmc6260457?pdf=renderLicence: CC BY-NC-ND

Cite this

Kurhanewicz, J., Vigneron, D. B., Ardenkjaer-Larsen, J. H., Bankson, J. A., Brindle, K., Cunningham, C. H., Gallagher, F. A., Keshari, K. R., Kjaer, A., Laustsen, C., Mankoff, D. A., Merritt, M. E., Nelson, S. J., Pauly, J. M., Lee, P., Ronen, S., Tyler, D. J., Rajan, S. S., Spielman, D. M., ... Rizi, R. (2019). Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology. Neoplasia (New York, N.Y.), 21(1), 1-16. https://doi.org/10.1016/j.neo.2018.09.006

Kurhanewicz, J, Vigneron, DB, Ardenkjaer-Larsen, JH, Bankson, JA, Brindle, K, Cunningham, CH, Gallagher, FA, Keshari, KR, Kjaer, A, Laustsen, C, Mankoff, DA, Merritt, ME, Nelson, SJ, Pauly, JM, Lee, P, Ronen, S, Tyler, DJ, Rajan, SS, Spielman, DM, Wald, L, Zhang, X, Malloy, CR & Rizi, R 2019, 'Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology', Neoplasia (New York, N.Y.), vol. 21, no. 1, pp. 1-16. https://doi.org/10.1016/j.neo.2018.09.006

@article{8e7d643ac76243e6a1763d81ad5d1c2f,

title = "Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology",

abstract = "This white paper discusses prospects for advancing hyperpolarization technology to better understand cancer metabolism, identify current obstacles to HP (hyperpolarized) 13C magnetic resonance imaging's (MRI's) widespread clinical use, and provide recommendations for overcoming them. Since the publication of the first NIH white paper on hyperpolarized 13C MRI in 2011, preclinical studies involving [1-13C]pyruvate as well a number of other 13C labeled metabolic substrates have demonstrated this technology's capacity to provide unique metabolic information. A dose-ranging study of HP [1-13C]pyruvate in patients with prostate cancer established safety and feasibility of this technique. Additional studies are ongoing in prostate, brain, breast, liver, cervical, and ovarian cancer. Technology for generating and delivering hyperpolarized agents has evolved, and new MR data acquisition sequences and improved MRI hardware have been developed. It will be important to continue investigation and development of existing and new probes in animal models. Improved polarization technology, efficient radiofrequency coils, and reliable pulse sequences are all important objectives to enable exploration of the technology in healthy control subjects and patient populations. It will be critical to determine how HP 13C MRI might fill existing needs in current clinical research and practice, and complement existing metabolic imaging modalities. Financial sponsorship and integration of academia, industry, and government efforts will be important factors in translating the technology for clinical research in oncology. This white paper is intended to provide recommendations with this goal in mind.",

keywords = "Animals, Carbon Isotopes, Disease Models, Animal, Humans, Magnetic Resonance Imaging/methods, Neoplasms/diagnosis, Reproducibility of Results, Translational Medical Research",

author = "John Kurhanewicz and Vigneron, {Daniel B} and Ardenkjaer-Larsen, {Jan Henrik} and Bankson, {James A} and Kevin Brindle and Cunningham, {Charles H} and Gallagher, {Ferdia A} and Keshari, {Kayvan R} and Andreas Kjaer and Christoffer Laustsen and Mankoff, {David A} and Merritt, {Matthew E} and Nelson, {Sarah J} and Pauly, {John M} and Philips Lee and Sabrina Ronen and Tyler, {Damian J} and Rajan, {Sunder S} and Spielman, {Daniel M} and Lawrence Wald and Xiaoliang Zhang and Malloy, {Craig R} and Rahim Rizi",

year = "2019",

month = jan,

doi = "10.1016/j.neo.2018.09.006",

language = "English",

volume = "21",

pages = "1--16",

journal = "Neoplasia (New York, N.Y.)",

issn = "1522-8002",

publisher = "Neoplasia Press",

number = "1",

}

TY - JOUR

T1 - Hyperpolarized 13C MRI

T2 - Path to Clinical Translation in Oncology

AU - Kurhanewicz, John

AU - Vigneron, Daniel B

AU - Ardenkjaer-Larsen, Jan Henrik

AU - Bankson, James A

AU - Brindle, Kevin

AU - Cunningham, Charles H

AU - Gallagher, Ferdia A

AU - Keshari, Kayvan R

AU - Kjaer, Andreas

AU - Laustsen, Christoffer

AU - Mankoff, David A

AU - Merritt, Matthew E

AU - Nelson, Sarah J

AU - Pauly, John M

AU - Lee, Philips

AU - Ronen, Sabrina

AU - Tyler, Damian J

AU - Rajan, Sunder S

AU - Spielman, Daniel M

AU - Wald, Lawrence

AU - Zhang, Xiaoliang

AU - Malloy, Craig R

AU - Rizi, Rahim

PY - 2019/1

Y1 - 2019/1

N2 - This white paper discusses prospects for advancing hyperpolarization technology to better understand cancer metabolism, identify current obstacles to HP (hyperpolarized) 13C magnetic resonance imaging's (MRI's) widespread clinical use, and provide recommendations for overcoming them. Since the publication of the first NIH white paper on hyperpolarized 13C MRI in 2011, preclinical studies involving [1-13C]pyruvate as well a number of other 13C labeled metabolic substrates have demonstrated this technology's capacity to provide unique metabolic information. A dose-ranging study of HP [1-13C]pyruvate in patients with prostate cancer established safety and feasibility of this technique. Additional studies are ongoing in prostate, brain, breast, liver, cervical, and ovarian cancer. Technology for generating and delivering hyperpolarized agents has evolved, and new MR data acquisition sequences and improved MRI hardware have been developed. It will be important to continue investigation and development of existing and new probes in animal models. Improved polarization technology, efficient radiofrequency coils, and reliable pulse sequences are all important objectives to enable exploration of the technology in healthy control subjects and patient populations. It will be critical to determine how HP 13C MRI might fill existing needs in current clinical research and practice, and complement existing metabolic imaging modalities. Financial sponsorship and integration of academia, industry, and government efforts will be important factors in translating the technology for clinical research in oncology. This white paper is intended to provide recommendations with this goal in mind.

AB - This white paper discusses prospects for advancing hyperpolarization technology to better understand cancer metabolism, identify current obstacles to HP (hyperpolarized) 13C magnetic resonance imaging's (MRI's) widespread clinical use, and provide recommendations for overcoming them. Since the publication of the first NIH white paper on hyperpolarized 13C MRI in 2011, preclinical studies involving [1-13C]pyruvate as well a number of other 13C labeled metabolic substrates have demonstrated this technology's capacity to provide unique metabolic information. A dose-ranging study of HP [1-13C]pyruvate in patients with prostate cancer established safety and feasibility of this technique. Additional studies are ongoing in prostate, brain, breast, liver, cervical, and ovarian cancer. Technology for generating and delivering hyperpolarized agents has evolved, and new MR data acquisition sequences and improved MRI hardware have been developed. It will be important to continue investigation and development of existing and new probes in animal models. Improved polarization technology, efficient radiofrequency coils, and reliable pulse sequences are all important objectives to enable exploration of the technology in healthy control subjects and patient populations. It will be critical to determine how HP 13C MRI might fill existing needs in current clinical research and practice, and complement existing metabolic imaging modalities. Financial sponsorship and integration of academia, industry, and government efforts will be important factors in translating the technology for clinical research in oncology. This white paper is intended to provide recommendations with this goal in mind.

KW - Animals

KW - Carbon Isotopes

KW - Disease Models, Animal

KW - Humans

KW - Magnetic Resonance Imaging/methods

KW - Neoplasms/diagnosis

KW - Reproducibility of Results

KW - Translational Medical Research

U2 - 10.1016/j.neo.2018.09.006

DO - 10.1016/j.neo.2018.09.006

M3 - Review

C2 - 30472500

SN - 1522-8002

VL - 21

SP - 1

EP - 16

JO - Neoplasia (New York, N.Y.)

JF - Neoplasia (New York, N.Y.)

IS - 1

ER -

Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this